News

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.

Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.

These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.

The first line treatment for restless legs syndrome—dopamine agonists—may be making a patient’s condition worse in the long-term, Winkelman told HCPLive at SLEEP 2024.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

Results showed eGFR was linked to having ≥ 20 adult teeth in postmenopausal women, highlighting increased tooth loss among participants with CKD versus those without.

A new study suggests the AHA's PREVENT risk calculator may reduce statin use for primary prevention, affecting eligibility for millions of adults.

At SLEEP 2024, Kolla shared tips to help his fellow practitioners for improving patient outcomes when dealing with patients with both sleep issues and psychiatric illnesses.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.

Disease activity was similar between patients with JIA undergoing a non-medical biological switch and those continuing the originator anti-TNF product.

Martin spoke about the barriers standing in the way of CPAP adherence in women with sleep apnea at SLEEP 2024.

This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.

Data collected from parallel online surveys revealed notable differences in IgA nephropathy treatment among patients and nephrologists from the US, EU5, Japan, and China.

A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.

At SLEEP 2024, Hartung discussed FloraWorks’ study finding patients on CBN had greater improvements in sleep quality than melatonin, but the difference was not significant.

Michael Freeman joins Veeral Sheth, MD to discuss the history of Ocutrx, its OcuLenz and OR-Bot products, and what he envisions in the next decade at the company.

In his RAD 2024 talk, Bissonnette presented recent data on 4 topical drugs for atopic dermatitis, including crisaborole and ruxolitinib.

A post-hoc analysis of the phase 2b ORIGIN study highlights atacicept’s impact on hematuria, with more patients achieving improvement and resolution at 36 weeks than those on placebo.

Lisa Swanson, MD, discusses the pathogenesis of atopic dermatitis and why she does not recommend elimination diets for her pediatric patients.

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.

At SLEEP 2024, Badr presented on novel treatments for central sleep apnea like phrenic nerve stimulation.